table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Analysis from 2022 to 2027
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Pulmonary Arterial Hypertension (PAH) Drugs Industry Impact
Chapter 2 Global Pulmonary Arterial Hypertension (PAH) Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Type
2.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Market Share by Type (2016-2021)
2.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2016-2021)
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Application
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Market Share by Application (2016-2021)
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Application (2016-2021)
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Regions
2.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Regions (2016-2021)
4.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
4.10 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
5.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
5.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
5.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
5.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
5.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
5.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
5.4.2 Canada Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
5.4.3 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 6 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
6.1 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
6.1.1 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
6.2 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
6.3 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
6.4 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
6.4.1 China Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
6.4.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
6.4.3 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 7 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
7.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
7.4.1 Germany Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.2 UK Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.3 France Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.4 Italy Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.5 Russia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.6 Spain Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.7 Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.8 Switzerland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
7.4.9 Poland Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 8 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
8.1 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
8.1.1 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
8.2 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
8.3 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
8.4 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
8.4.1 India Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
8.4.2 Pakistan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
9.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
9.2 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
9.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
9.4 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
9.4.1 Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.2 Thailand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.3 Singapore Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.4 Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.5 Philippines Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.6 Vietnam Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
9.4.7 Myanmar Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 10 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
10.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
10.1.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
10.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
10.3 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
10.4 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
10.4.1 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.3 Iran Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.5 Israel Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.6 Iraq Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.7 Qatar Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.8 Kuwait Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
10.4.9 Oman Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 11 Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
11.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
11.1.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
11.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
11.3 Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
11.4 Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
11.4.1 Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
11.4.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
11.4.3 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
11.4.4 Algeria Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
11.4.5 Morocco Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 12 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
12.1 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
12.2 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
12.3 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
12.4 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Top Countries
12.4.1 Australia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
12.4.2 New Zealand Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 13 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis
13.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Value Analysis
13.1.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Under COVID-19
13.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Types
13.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Structure by Application
13.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume by Major Countries
13.4.1 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.2 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.3 Columbia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.4 Chile Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.5 Venezuela Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.6 Peru Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
13.4.8 Ecuador Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Pulmonary Arterial Hypertension (PAH) Drugs Business
14.1 Pfizer
14.1.1 Pfizer Company Profile
14.1.2 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Glaxosmithkline
14.2.1 Glaxosmithkline Company Profile
14.2.2 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Novartis
14.3.1 Novartis Company Profile
14.3.2 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 United Therapeutics
14.4.1 United Therapeutics Company Profile
14.4.2 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 AstraZeneca
14.5.1 AstraZeneca Company Profile
14.5.2 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Merck
14.6.1 Merck Company Profile
14.6.2 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Bayer Healthcare
14.7.1 Bayer Healthcare Company Profile
14.7.2 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Actelion Pharmaceuticals
14.8.1 Actelion Pharmaceuticals Company Profile
14.8.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Daiichi Sankyo
14.9.1 Daiichi Sankyo Company Profile
14.9.2 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Northern Therapeutics
14.10.1 Northern Therapeutics Company Profile
14.10.2 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Aires Pharmaceuticals
14.11.1 Aires Pharmaceuticals Company Profile
14.11.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Arena Pharmaceuticals
14.12.1 Arena Pharmaceuticals Company Profile
14.12.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Berlin Cures
14.13.1 Berlin Cures Company Profile
14.13.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 Eiger BioPharmaceuticals
14.14.1 Eiger BioPharmaceuticals Company Profile
14.14.2 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Reata Pharmaceuticals
14.15.1 Reata Pharmaceuticals Company Profile
14.15.2 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Specification
14.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2022-2027)
15.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Value and Growth Rate Forecast (2022-2027)
15.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Type (2022-2027)
15.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2022-2027)
15.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2022-2027)
15.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Volume Forecast by Application (2022-2027)
15.5 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
